Professor and Director of the Center for Drug Design and Development, Ph.D., 1974, University of Minnesota, Minneapolis. Design and synthesis of small-molecule therapeutic agents. Medicinal chemistry of anti-cancer and critical care drugs.
Distinguished University Professor, Ph.D., 1975, Duke University. Mechanistic enzymology. Design of mechanism-based inhibitors of enzymes. Studies on lipoxygenase, its inhibition, and its role in leukotriene biosynthesis. Leukotriene and lipoxin antagonism.
Associate Professor, Ph.D., 1977, University of California at Los Angeles. Site-directed action of immunotoxic proteins of venom origin. Destruction of selective lymphocyte subtypes by membrane-lytic toxins. Animal model studies of the immunologic course and suppression of autoimmune diseases affecting the nervous system: e.g., experimental autoimmune myasthenia gravis. Applications of membrane-active toxin components in cancer treatment.
Professor, Ph.D., 1966, University of Chicago. Models in drug design. Redox-reactive agents for acetylcholine receptors and other sites of cholinergic action. Peptides as immunosuppressive and tolerance-inducing agents. Pyrroloquinoline quinone (PQQ) analogues as probes in flavin and PQQ-requiring enzyme systems. Novel reverse transcriptase inhibitors affecting retroviral mutation rates.
Associate Professor, Ph.D., Purdue University, 1985. Chemically modified electrodes, microelectrodes, biomimetic electrochemistry, electrochemical and spectroelectrochemical methods for characterization and analysis; redox properties of metal complexes; photochemistry and photophysics of coordination complexes.
Professor and Chair, Ph.D., 1989, University of Michigan. Immunoregulation in and basic studies on the mechanism underlying autoimmune diabetes, selective reduction or modulation of T-cells in autoimmune disease. Macrophage nitric oxide mediated beta cell destruction in autoimmune diabetes. Determination of candidate autoantigens recognized by CD8 T-cells using molecular methods.
Professor, Ph.D., University of Rochester Neuroscience. Chair, The University of Toledo College of Pharmacy Department of Pharmacology
Research Professor, Ph.D., 1972, Lorand Eotvos University of Science, Budapest. Theoretical studies in drug design based on molecular structure in the gas and solution phases. Studies of conformation in hydrogen-bonded systems and structural parameters related to drug design.
Associate Professor, Ph.D., 1983, Massachusetts Institute of Technology. Design, construction, and deployment of relational databases relevant to drug discovery and design. Gene array and informatic approaches to investigating heterotrimeric G protein mediated signal transduction pathways. Use of small molecule synthesis and molecular biological methodology to explore functional roles and drug target potential of protein lipophilic modifications such as myristylation and palmitoylation of heterotrimeric G protein alpha subunit N-termini..
Professor, Ph.D., 1971, University of Alberta. Structural characterization of drugs, drug precursors, drug-related metabolites, and drug-receptor complexes using single crystal X-ray diffraction and both solution and solid-state NMR spectroscopy. This work combines the use of structural information with computer molecular modeling into synthetic strategies for new drugs, and toward understanding the modes of action of known drugs.
Associate Professor, Ph.D., 1977, University of California at Berkeley. Enzymes as targets in drug design; design, synthesis and enzymology of mechanism-based enzyme inhibitors. ADP-ribosylation and a novel mechanism of metabolic regulation; ADP-ribosyltransferases as targets for drug design; cytochrome P-450 inhibitors.
Associate Professor, Ph.D., 1975, Oxford University. Studies of enzyme inhibitors of natural and synthetic origin for development of potential anti-AIDS therapeutics. Isolation and characterization of biologically active natural products.
Associate Professor, M.D 1982, Ph.D. 1983, Max Planck Institute for Biochemistry Munich and University of Konstanz. The structure of MHC bound antigenic peptides computational simulation and experimental tests. Structure function relationships of cytokine receptors.
Professor, Ph.D., 1977, University of California at Berkeley. Recognition of antigens by T-cells; targeting T-cells in drug design. Molecular analysis of the autoimmune disease myasthenia gravis using a murine model. Design of immunomodulatory drugs.
| Graduate Chmn.| Graduate Courses | Research Interests | CD3 | Seminar ]